{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:38:05Z","timestamp":1792395485282,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The NLRP3 inflammasome is a well-studied target for the treatment of multiple inflammatory diseases, but how to promote the current therapeutics remains a large challenge. CRISPR\/Cas9, as a gene editing tool, allows for direct ablation of NLRP3 at the genomic level. In this study, we screen an optimized cationic lipid-assisted nanoparticle (CLAN) to deliver Cas9 mRNA (mCas9) and guide RNA (gRNA) into macrophages. By using CLAN encapsulating mCas9 and gRNA-targeting NLRP3 (gNLRP3) (CLAN\n                    <jats:sub>mCas9\/gNLRP3<\/jats:sub>\n                    ), we disrupt NLRP3 of macrophages, inhibiting the activation of the NLRP3 inflammasome in response to diverse stimuli. After intravenous injection, CLAN\n                    <jats:sub>mCas9\/gNLRP3<\/jats:sub>\n                    mitigates acute inflammation of LPS-induced septic shock and monosodium urate crystal (MSU)-induced peritonitis. In addition, CLAN\n                    <jats:sub>mCas9\/gNLRP3<\/jats:sub>\n                    treatment improves insulin sensitivity and reduces adipose inflammation of high-fat-diet (HFD)-induced type 2 diabetes (T2D). Thus, our study provides a promising strategy for treating NLRP3-dependent inflammatory diseases and provides a carrier for delivering CRISPR\/Cas9 into macrophages.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-06522-5","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T06:14:26Z","timestamp":1538374466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases"],"prefix":"10.1038","volume":"9","author":[{"given":"Congfei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaige","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-4456","authenticated-orcid":false,"given":"Zhen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9208","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"6522_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229\u2013265 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"6522_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.immuni.2013.08.037","volume":"39","author":"H Wen","year":"2013","unstructured":"Wen, H., Miao, E. A. & Ting, J. P. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 39, 432\u2013441 (2013).","journal-title":"Immunity"},{"key":"6522_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407\u2013420 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"6522_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He, Y., Hara, H. & Nunez, G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41, 1012\u20131021 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"6522_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29","author":"BK Davis","year":"2011","unstructured":"Davis, B. K., Wen, H. & Ting, J. P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29, 707\u2013735 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"6522_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.it.2011.05.004","volume":"32","author":"D De Nardo","year":"2011","unstructured":"De Nardo, D. & Latz, E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 32, 373\u2013379 (2011).","journal-title":"Trends Immunol."},{"key":"6522_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677\u2013687 (2015).","journal-title":"Nat. Med."},{"key":"6522_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan, Y. et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62\u201373 (2015).","journal-title":"Cell"},{"key":"6522_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.4049\/jimmunol.1601745","volume":"198","author":"L Jin","year":"2017","unstructured":"Jin, L., Batra, S. & Jeyaseelan, S. Deletion of Nlrp3 augments survival during polymicrobial sepsis by decreasing autophagy and enhancing phagocytosis. J. Immunol. 198, 1253\u20131262 (2017).","journal-title":"J. Immunol."},{"key":"6522_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00227-x","volume":"8","author":"T Tang","year":"2017","unstructured":"Tang, T. et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat. Commun. 8, 202 (2017).","journal-title":"Nat. Commun."},{"key":"6522_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263\u2013269 (2015).","journal-title":"Nat. Med."},{"key":"6522_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka, M. T. et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature 493, 674\u2013678 (2013).","journal-title":"Nature"},{"key":"6522_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"6522_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179\u2013188 (2011).","journal-title":"Nat. Med."},{"key":"6522_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ni.2022","volume":"12","author":"H Wen","year":"2011","unstructured":"Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408\u2013415 (2011).","journal-title":"Nat. Immunol."},{"key":"6522_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"6522_CR17","doi-asserted-by":"publisher","first-page":"10480","DOI":"10.1073\/pnas.1201836109","volume":"109","author":"M Inoue","year":"2012","unstructured":"Inoue, M., Williams, K. L., Gunn, M. D. & Shinohara, M. L. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 109, 10480\u201310485 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6522_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248\u2013255 (2015).","journal-title":"Nat. Med."},{"key":"6522_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"6522_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633\u2013652 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6522_CR21","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"PN Hawkins","year":"2003","unstructured":"Hawkins, P. N., Lachmann, H. J. & McDermott, M. F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583\u20132584 (2003).","journal-title":"N. Engl. J. Med."},{"key":"6522_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nbt0508-485b","volume":"26","author":"M Ratner","year":"2008","unstructured":"Ratner, M. IL-1 trap go-ahead. Nat. Biotechnol. 26, 485 (2008).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi, M. et al. Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome. J. Cell Biol. 187, 61\u201370 (2009).","journal-title":"J. Cell Biol."},{"key":"6522_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/art.20115","volume":"50","author":"MH Buch","year":"2004","unstructured":"Buch, M. H. et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum. 50, 725\u2013728 (2004).","journal-title":"Arthritis Rheum."},{"key":"6522_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40259-017-0224-7","volume":"31","author":"A Mistry","year":"2017","unstructured":"Mistry, A., Savic, S. & van der Hilst, J. C. H. Interleukin-1 blockade: an update on emerging indications. BioDrugs 31, 207\u2013221 (2017).","journal-title":"BioDrugs"},{"key":"6522_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2015.00262","volume":"6","author":"BZ Shao","year":"2015","unstructured":"Shao, B. Z., Xu, Z. Q., Han, B. Z., Su, D. F. & Liu, C. NLRP3 inflammasome and its inhibitors: a review. Front. Pharmacol. 6, 262 (2015).","journal-title":"Front. Pharmacol."},{"key":"6522_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"6522_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"6522_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347\u2013355 (2014).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR30","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219\u20133238 (2017).","journal-title":"J. Exp. Med."},{"key":"6522_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature.2016.20988","volume":"539","author":"D Cyranoski","year":"2016","unstructured":"Cyranoski, D. CRISPR gene-editing tested in a person for the first time. Nature 539, 479 (2016).","journal-title":"Nature"},{"key":"6522_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186\u2013191 (2015).","journal-title":"Nature"},{"key":"6522_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411 (2016).","journal-title":"Science"},{"key":"6522_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"6522_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson, N. E. et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).","journal-title":"Nat. Commun."},{"key":"6522_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1021\/acsnano.6b04261","volume":"11","author":"L Li","year":"2017","unstructured":"Li, L. et al. Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice. ACS Nano 11, 95\u2013111 (2017).","journal-title":"ACS Nano"},{"key":"6522_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328\u2013333 (2016).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/anie.201610209","volume":"56","author":"JB Miller","year":"2017","unstructured":"Miller, J. B. et al. Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed. Engl. 56, 1059\u20131063 (2017).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"6522_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/cr.2017.16","volume":"27","author":"C Jiang","year":"2017","unstructured":"Jiang, C. et al. A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res. 27, 440\u2013443 (2017).","journal-title":"Cell Res."},{"key":"6522_CR40","doi-asserted-by":"publisher","first-page":"25481","DOI":"10.1021\/acsami.7b08163","volume":"9","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Biodegradable amino-ester nanomaterials for Cas9 mRNA delivery in vitro and in vivo. ACS Appl. Mater. Interfaces 9, 25481\u201325487 (2017).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"6522_CR41","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"6522_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12617","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Efficient and transgene-free genome editing in wheat through transient expression of CRISPR\/Cas9 DNA or RNA. Nat. Commun. 7, 12617 (2016).","journal-title":"Nat. Commun."},{"key":"6522_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02706-7","volume":"9","author":"Y Yoon","year":"2018","unstructured":"Yoon, Y. et al. Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat. Commun. 9, 412 (2018).","journal-title":"Nat. Commun."},{"key":"6522_CR44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179\u20131187 (2017).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00505-8","volume":"8","author":"HF Moffett","year":"2017","unstructured":"Moffett, H. F. et al. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat. Commun. 8, 389 (2017).","journal-title":"Nat. Commun."},{"key":"6522_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","volume":"1","author":"K Lee","year":"2017","unstructured":"Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889\u2013901 (2017).","journal-title":"Nat. Biomed. Eng."},{"key":"6522_CR47","doi-asserted-by":"publisher","first-page":"12029","DOI":"10.1002\/anie.201506030","volume":"54","author":"W Sun","year":"2015","unstructured":"Sun, W. et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. Engl. 54, 12029\u201312033 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"6522_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73\u201380 (2015).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR49","doi-asserted-by":"publisher","first-page":"13787","DOI":"10.1038\/ncomms13787","volume":"7","author":"Chenglu Xiao","year":"2016","unstructured":"Xiao, C., et al. Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafish. Nat. Commun. 7, 13787 (2016).","journal-title":"Nature Communications"},{"key":"6522_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hep.26654","volume":"59","author":"S Lv","year":"2014","unstructured":"Lv, S. et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 59, 385\u2013394 (2014).","journal-title":"Hepatology"},{"key":"6522_CR51","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1073\/pnas.1502159112","volume":"112","author":"L Chen","year":"2015","unstructured":"Chen, L. et al. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc. Natl Acad. Sci. USA 112, 10002\u201310007 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6522_CR52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrd2591","volume":"9","author":"RA Petros","year":"2010","unstructured":"Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615\u2013627 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6522_CR53","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941\u2013951 (2015).","journal-title":"Nat. Biotechnol."},{"key":"6522_CR54","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","volume":"32","author":"K Xiao","year":"2011","unstructured":"Xiao, K. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32, 3435\u20133446 (2011).","journal-title":"Biomaterials"},{"key":"6522_CR55","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1021\/nl302638g","volume":"12","author":"JL Perry","year":"2012","unstructured":"Perry, J. L. et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12, 5304\u20135310 (2012).","journal-title":"Nano Lett."},{"key":"6522_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant, H., Pfizenmaier, K. & Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 10, 45\u201365 (2003).","journal-title":"Cell Death Differ."},{"key":"6522_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nmeth.4293","volume":"14","author":"KA Schaefer","year":"2017","unstructured":"Schaefer, K. A. et al. Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat. Methods 14, 547\u2013548 (2017).","journal-title":"Nat. Methods"},{"key":"6522_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd.2016.280","volume":"16","author":"H Yin","year":"2017","unstructured":"Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov. 16, 387\u2013399 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6522_CR59","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"HX Wang","year":"2017","unstructured":"Wang, H. X. et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874\u20139906 (2017).","journal-title":"Chem. Rev."},{"key":"6522_CR60","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","volume":"28","author":"R Mout","year":"2017","unstructured":"Mout, R., Ray, M., Lee, Y. W., Scaletti, F. & Rotello, V. M. In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges. Bioconjug. Chem. 28, 880\u2013884 (2017).","journal-title":"Bioconjug. Chem."},{"key":"6522_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2011.07.035","volume":"156","author":"XZ Yang","year":"2011","unstructured":"Yang, X. Z. et al. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J. Control Release 156, 203\u2013211 (2011).","journal-title":"J. Control Release"},{"key":"6522_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2016.02.031","volume":"88","author":"CF Xu","year":"2016","unstructured":"Xu, C. F. et al. Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery. Biomaterials 88, 48\u201359 (2016).","journal-title":"Biomaterials"},{"key":"6522_CR63","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06522-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06522-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06522-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:42:24Z","timestamp":1671543744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06522-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6522"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06522-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"assertion":[{"value":"24 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4092"}}